Severe Low Sugar to be Treated With Nasal Spray of Glucagon

The FDA has approved a nasal powder in a single-use dispenser to treat severe hypoglycemia in patients with diabetes.

FDA has approved the first glucagon therapy that can be given without injection. Baqsimi, approved for patients aged 4 years and older, is the first approved glucagon therapy that can be given without an injection.

Approval was based on //three studies — two adult studies (roughly 150 patients) and a pediatric study (roughly 50 patients) that compared a single dose of glucagon powder to a dose of injection.

Hypoglycemia (Low Blood Sugar) - Causes, Diagnosis, Treatment, Prevention
Hypoglycemia or low blood sugar often occurs in diabetic patients on insulin treatment. Other conditions like hormone deficiencies can also cause hypoglycemia.

‘The FDA has approved a nasal powder in a single-use dispenser to treat severe hypoglycemia in patients with diabetes. ’

Efficacy and safety outcomes were similar across studies.

The drug carries a warning for patients who have conditions that might cause low levels of releasable glucose in the liver (adrenal insufficiency, chronic hypoglycemia, long periods of fasting).

Additionally, it shouldn't be given to patients with pancreatic or adrenal gland tissue tumors or sensitivities to the drug's ingredients.

Quiz on Diabetes Medications
How much do you know about the medications used to treat diabetes? Here are a few questions you could attempt to test your knowledge.

Common side effects include headache, nasal congestion, nausea, upper respiratory tract irritation, vomiting, and watery eyes.

The list price for a single pack of Baqsimi is $280.80, according to the manufacturer.

Glucose Monitoring can Prevent Hypoglycemia in Heart Patients
Regularly monitoring glucose levels can help prevent hypoglycaemia in hospitalized patients with coronary artery disease.

Source-Medindia

Continuous Glucose Monitors Reduce Incidence of Hypoglycemia
Hypoglycemia or low blood sugar levels can be controlled in type 1 diabetic patients with Continuous Glucose Monitors(CGM).